Active, Not Recruiting
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants - CA209-8D3
Updated: 6 July, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - A patient with RCC with distant metastasis treated for the first time with nivolumab Exclusion Criteria: - Patients who have participated in some trials with immuno-checkpoint blockade before or after treatment with nivolumab after diagnosis with RCC Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information